GE HealthCare AI Ultrasound Aims to Cut Exam Time by 65%

Edgen Stock·Feb 26 2026, 18:08

Share to

Share to

Copy link

Key Takeaways

GE HealthCare has launched its next-generation LOGIQ ultrasound portfolio, integrating artificial intelligence to significantly boost diagnostic efficiency and address major clinical needs. The new systems are designed to reduce sonographer workload and provide new, non-invasive tools for assessing widespread conditions like fatty liver disease.

AI-Driven Efficiency: The new Auto Abdominal Suite 2.0 uses AI to automate measurements, which GE HealthCare claims can reduce system interactions by 80% and speed up measurements by 65%.
Major Clinical Target: A new tool, Ultrasound-Guided Fat Fraction (UGFF), offers a non-invasive way to quantify liver fat, targeting the nearly 40% of the global population affected by fatty liver disease.
Strategic Market Position: The systems, set to debut at ECR 2026, feature an open platform that integrates third-party applications, positioning GE HealthCare to capture a larger share of the advanced medical imaging market.

AI-Powered Suite Reduces System Interactions by 80%

On February 26, GE HealthCare announced the launch of its next-generation LOGIQ general imaging ultrasound portfolio, including the E10 Series, Fortis, and Totus models. The core of the upgrade is the AI-powered Auto Abdominal Suite 2.0, an automation toolkit designed to combat sonographer burnout and increase clinic throughput. According to company data, these tools can accelerate measurements by 65% and reduce necessary system interactions by a remarkable 80%. This efficiency gain directly addresses the repetitive, keystroke-intensive nature of ultrasound exams. Further enhancing its workflow, the new platform integrates third-party applications alongside GE's own Verisound digital offerings, allowing hospitals to consolidate specialized AI tools directly onto the scanner.

New Tool Targets Underdiagnosed Fatty Liver Disease

A key clinical advancement in the new portfolio is the Ultrasound-Guided Fat Fraction (UGFF) tool, designed to confront the silent epidemic of fatty liver disease. The condition, also known as Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD), affects nearly 40% of the global population but remains chronically underdiagnosed because the standard diagnostic method is an invasive and painful liver biopsy. The UGFF tool provides clinicians with a non-invasive method to quantify liver fat at the point of care. This shifts the diagnosis from a subjective visual assessment to a consistent, objective metric, enabling better monitoring of disease progression and the personalization of patient care.